as 02-10-2025 11:39am EST
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Founded: | 2015 | Country: | United Kingdom |
Employees: | N/A | City: | LONDON |
Market Cap: | 482.5M | IPO Year: | N/A |
Target Price: | $7.83 | AVG Volume (30 days): | 1.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.31 | EPS Growth: | N/A |
52 Week Low/High: | $2.52 - $5.02 | Next Earning Date: | 03-26-2025 |
Revenue: | $1,000,000 | Revenue Growth: | -88.89% |
Revenue Growth (this year): | -16.86% | Revenue Growth (next year): | 54.47% |
MREO Breaking Stock News: Dive into MREO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Insider Monkey
a month ago
TipRanks
2 months ago
GuruFocus.com
2 months ago
MT Newswires
2 months ago
MT Newswires
2 months ago
GlobeNewswire
3 months ago
The information presented on this page, "MREO Mereo BioPharma Group plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.